Brokerages expect Molecular Templates, Inc. (NASDAQ:MTEM – Get Rating) to post $6.88 million in sales for the current quarter, according to Zacks. Two analysts have provided estimates for Molecular Templates’ earnings. The highest sales estimate is $8.75 million and the lowest is $5.00 million. Molecular Templates posted sales of $3.22 million in the same quarter last year, which suggests a positive year over year growth rate of 113.7%. The firm is scheduled to report its next earnings results on Monday, January 1st.
According to Zacks, analysts expect that Molecular Templates will report full year sales of $26.17 million for the current year, with estimates ranging from $10.50 million to $48.00 million. For the next year, analysts anticipate that the business will report sales of $29.17 million, with estimates ranging from $10.50 million to $57.00 million. Zacks’ sales averages are a mean average based on a survey of analysts that cover Molecular Templates.
Molecular Templates (NASDAQ:MTEM – Get Rating) last released its quarterly earnings results on Monday, March 28th. The biotechnology company reported ($0.18) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.40) by $0.22. Molecular Templates had a negative return on equity of 96.66% and a negative net margin of 214.51%.
A number of large investors have recently made changes to their positions in the stock. Bellevue Group AG boosted its stake in Molecular Templates by 13.0% during the 3rd quarter. Bellevue Group AG now owns 10,878,003 shares of the biotechnology company’s stock valued at $72,991,000 after purchasing an additional 1,249,382 shares during the period. BlackRock Inc. boosted its stake in Molecular Templates by 8.7% during the 4th quarter. BlackRock Inc. now owns 2,850,901 shares of the biotechnology company’s stock valued at $11,175,000 after purchasing an additional 228,321 shares during the period. Adage Capital Partners GP L.L.C. lifted its position in shares of Molecular Templates by 18.2% in the 4th quarter. Adage Capital Partners GP L.L.C. now owns 1,200,000 shares of the biotechnology company’s stock worth $4,704,000 after acquiring an additional 185,000 shares during the period. Kingdon Capital Management L.L.C. lifted its position in shares of Molecular Templates by 1.0% in the 3rd quarter. Kingdon Capital Management L.L.C. now owns 1,021,317 shares of the biotechnology company’s stock worth $6,853,000 after acquiring an additional 9,822 shares during the period. Finally, Geode Capital Management LLC lifted its position in shares of Molecular Templates by 4.1% in the 4th quarter. Geode Capital Management LLC now owns 683,792 shares of the biotechnology company’s stock worth $2,680,000 after acquiring an additional 26,884 shares during the period. Hedge funds and other institutional investors own 66.29% of the company’s stock.
Shares of NASDAQ MTEM traded down $0.16 during mid-day trading on Friday, hitting $2.95. 3,899 shares of the company traded hands, compared to its average volume of 184,937. The business has a 50 day moving average of $2.74 and a two-hundred day moving average of $4.05. The company has a current ratio of 3.18, a quick ratio of 3.18 and a debt-to-equity ratio of 0.54. Molecular Templates has a 1 year low of $2.22 and a 1 year high of $9.63.
About Molecular Templates (Get Rating)
Molecular Templates, Inc, a clinical stage biopharmaceutical company, focuses on the discovery and development of biologic therapeutics for the treatment of cancer and other serious diseases. The company primarily develops a pipeline of therapies through its proprietary biologic engineered toxin body (ETB) drug platform.
- Get a free copy of the StockNews.com research report on Molecular Templates (MTEM)
- 3 Undervalued Stocks The Insiders Are Buying
- The Market For Gamestop Is Near A Turning Point
- PayPal Stock is Still Ready for Bargain Hunting
- It’s Personal: 3 Personal Care Stocks to Own in Volatile Markets
- Conagra Stock Has More Room to Grow
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Molecular Templates Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Molecular Templates and related companies with MarketBeat.com's FREE daily email newsletter.